carboxyamidotriazole
Small moleculeexperimental
Carboxyamidotriazole is a calcium channel blocker that blocks voltage-gated and ligand-gated calcium channels and has been investigated as an anti-cancer drug in vitro. — Wikipedia
Clinical trial activity
7 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Oct 1, 1994 (NCT00019019)
Timeline
Indications
Studied for
- Brain Neoplasms · Phase 1
- Breast Neoplasms · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Renal Cell · Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Glioblastoma · Phase 2
- Gliosarcoma · Phase 2
- Hamartoma · Phase 2
- Intestinal Neoplasms · Phase 1
- Kidney Neoplasms · Phase 2
- Lung Neoplasms · Phase 1
- Lymphoma · Phase 1
- Melanoma · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 2
Mechanism of action
- Tyrosine-protein kinase V-ABLINHIBITOR
ABL inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
NC(=O)c1nnn(Cc2cc(Cl)c(C(=O)c3ccc(Cl)cc3)c(Cl)c2)c1N- Mol. weight
- 424.68 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCarboxyamidotriazole ↗
- ChEMBLCHEMBL95431 ↗
Also known as
- 1h-1,2,3-triazole-4-carboxamide, 5-amino-1-((3,5-dichloro-4-(4-chlorobenzoyl)phenyl)methyl)-
- 4-cai
- cai
- cai
- carboxyamidotriazole
- carboxyamidotriazole
- carboxyamidotriazole
- carboxyamidotriazole
- carboxyamido-triazole
- l651582
- l 651582
- l-651582
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00006486 | Phase 2 | Oct 1, 2000 | Cancer and Leukemia Group B (CALGB), National Cancer Institute (NCI) |
| NCT00004146 | Phase 2 | Mar 1, 2000 | National Cancer Institute (NCI) |
| NCT00005045 | Phase 2 | Mar 1, 2000 | Eastern Cooperative Oncology Group, National Cancer Institute (NCI), University of Pittsburgh |
| NCT00003869 | Phase 3 | Apr 1, 1999 | National Cancer Institute (NCI), North Central Cancer Treatment Group |
| NCT00003249 | Phase 1 | May 1, 1998 | National Cancer Institute (NCI), University of Chicago |
| NCT00019461 | Phase 2 | Apr 1, 1998 | National Cancer Institute (NCI) |
| NCT00019019 | Phase 1 | Oct 1, 1994 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 7 | 5 | 3 | 1994 |
| Cancer and Leukemia Group B (CALGB) | Academic/Hospital | 1 | 0 | 1 | 2000 |
| Eastern Cooperative Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2000 |
| National Institutes of Health (NIH) | Government | 1 | 1 | 1 | 1994 |
| North Central Cancer Treatment Group | Academic/Hospital | 1 | 0 | 1 | 1999 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 1998 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2000 |
7 organizations
Page 1 / 1